Trial Profile
A phase III long-term study of HP-3000 in patients with Parkinson's disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Hisamitsu Pharmaceutical
- 16 Nov 2017 Status changed from recruiting to completed.
- 04 Feb 2015 New trial record
- 16 Dec 2014 Status changed from planning to recruiting, as reported by the Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information record.